within Pharmacolibrary.Drugs.ATC.L;

model L04AG03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0032500000000000003,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Natalizumab is a humanized monoclonal antibody that selectively binds to the α4-subunit of integrins on the surface of leukocytes and inhibits their adhesion to endothelial cells, thereby preventing migration of immune cells into the brain and spinal cord. It is primarily approved for the treatment of relapsing forms of multiple sclerosis and is also used for Crohn's disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with relapsing-remitting multiple sclerosis, healthy volunteers; both male and female. Standard dosing regimen.</p><h4>References</h4><ol><li>John F Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen, Douglas L Arnold, Helmut Butzkueven, Gary R Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Kexuan Li, Liesel Dsilva, Marie Toukam, Kyle Ferber, Jihee Sohn, Holly Engelman, Tyler Lasky,Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.,Neurology(R) neuroimmunology & neuroinflammation,2024<a href='https://pubmed.ncbi.nlm.nih.gov/39393045/'>https://pubmed.ncbi.nlm.nih.gov/39393045/</a></li><li>Jose M Serra López-Matencio, Yaiza Pérez García, Virginia Meca-Lallana, Raquel Juárez-Sánchez, Angeles Ursa, Lorena Vega-Piris, Dora Pascual-Salcedo, Annick de Vries, Theo Rispens, Cecilia Muñoz-Calleja,Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses.,Frontiers in neurology,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34690914/'>https://pubmed.ncbi.nlm.nih.gov/34690914/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG03;
